This article was originally published in The Tan Sheet
Company intends to invest $30-40 mil. in the "formulation of existing drugs that are either off patent or will be coming off patent into Scherer delivery systems," such as Scherersol, Zydis and Pulsincap, Scherer reported at its annual meeting in Troy, Mich. on Sept. 29. Many OTC cold products already incorporate the Scherersol liquid formulation technology for encapsulation ("The Tan Sheet" Aug. 23, p. 2). Scherer increased R&D spending 41% in the first quarter of fiscal 1995, while earnings per share rose 31%. Scherer anticipates "net income growth between 20-25% on average over the next several years," the firm said
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC